Geoffrey Cash Gurtner, MD
Plastic and Reconstructive Surgery · Tucson
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
- Since medical school
- 37 years
- University of California, San Francisco School of Medicine, 1989
Offices
1 location · Banner-University Medical Group · 1,066 clinicians in this group
Hospitals listed: Banner - University Medical Center Tucson Campus. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Gurtner’s office at (520) 694-2873 to ask if they take your plan before you enroll.
California Medical Board record
Licence A93283 · Current
Licensed to practise in California · since 2005 · expires 2027-06-30 · University of California San Francisco School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Plastic Surgery - Plastic Surgery
- American Board of Surgery - Surgery
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Banner - University Medical Center Tucson CampusTucson, AZAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Banner Health, which runs 33 hospitals in 6 statesHome of University of Arizona Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 2 of 5 · 68% would definitely recommend itOverall rating: 3 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.69 (3.93 to 7.45) · 2,236 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.369, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.4, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.642, Oct 2024 – Sep 2025
See every measure and the patient survey for Banner - University Medical Center Tucson Campus
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 4 better, 3 the same, 0 worse of 7 measures. Readmissions: 2 better, 8 the same, 0 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.69 (3.93 to 7.45) · 2,236 cases | Worse | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.369 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.4 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.642 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.35 (0.5 to 2.2) · 1,658 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.09 (0.84 to 1.34) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 179.64 (138.61 to 220.67) · 178 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.7 · 71 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 9.9 · 49 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 107 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10.1 · 237 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14 · 386 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 11.6 · 365 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.2 · 4,004 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.27 (0.08 to 0.46) · 6,096 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.31 (0.12 to 0.51) · 6,470 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2.64 (1.24 to 4.04) · 926 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.89 (1.65 to 4.12) · 2,177 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.93 (4.58 to 15.29) · 835 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.37 (2.47 to 8.27) · 912 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.42 (0.05 to 2.8) · 591 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.3 (0 to 0.81) · 5,842 cases | No different | Jul 2022 – Jun 2024 |
| MRSA BacteremiaInfections | 0.916 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.534 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.979 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.1 · 192 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20 · 586 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 1 · 128 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -17.6 · 257 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -18.7 · 390 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 15.7 · 814 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5 (3.8 to 6.5) · 634 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 9.8 (8 to 11.8) · 634 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.5 · 27 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11 · 106 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 167 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 14.9 (11.6 to 19.1) · 1,247 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.2) · 1,129 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,281 patients answered, 21% of those asked)
| Cleanliness | 3 |
| Nurse communication | 2 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 3 |
| Room was "always" clean | 63% |
| Nurses "always" communicated well | 72% |
| Doctors "always" communicated well | 72% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 83% |
| Yes, staff "did" give patients information about help after discharge | 81% |
| Doctors "always" explained things so they could understand | 64% |
| Doctors "always" listened carefully | 71% |
| Doctors "always" treated them with courtesy and respect | 81% |
| Patients who gave a rating of "9" or "10" (high) | 67% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 66% |
| Nurses "always" listened carefully | 67% |
| Nurses "always" treated them with courtesy and respect | 81% |
| "Always" quiet at night | 49% |
| "YES", patients would definitely recommend the hospital | 68% |
| Staff "always" explained possible side effects | 43% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
Original Medicare doctor bills
$14,609
Medicare paid this office $14,609 for 17 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
Procedures Medicare counted
| Mastectomy | 15 | More than 72% of doctors who do this |
| Melanoma (skin cancer) excision | 1-10 | None |
| Removal of tissue | 1-10 | None |
Procedures year by year
| Procedure | 2018 | 2019 | 2020 | 2021 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Removal of skin and tissue, 20.0 sq cm or less | 48 | 48 | – | – | – | – |
| Removal of muscle and/or tissue, 20.0 sq cm or less | – | – | 30 | – | – | – |
Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.
Who their Medicare patients are
17 Original Medicare patients in 2024. Average age 70 · Women 100% · Also on Medicaid 0% · Health risk score 0.71. At or below the middle of the specialty; the typical plastic and reconstructive surgery clinician is at 1.21.
Conditions among them: Cancer 75%.
The office billed $58,998, Medicare allowed $18,281 and paid $14,609; for 56 services of 17 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 17 | 56 | 70 | 0.71 | $58,998 | $14,609 |
| 2023 | 21 | 68 | 71 | 1.13 | $72,937 | $17,655 |
| 2021 | 22 | 105 | 74 | 3.38 | $52,828 | $9,414 |
| 2020 | 26 | 196 | 71 | 2.53 | $127,811 | $20,985 |
| 2019 | 33 | 120 | 75 | 2.11 | $76,002 | $12,563 |
| 2018 | 43 | 123 | 74 | 3.04 | $43,479 | $10,279 |
| 2017 | 46 | 207 | 70 | 3.13 | $122,849 | $20,713 |
| 2016 | 53 | 143 | 68 | 2.77 | $150,534 | $22,343 |
| 2015 | 63 | 167 | 71 | 2.63 | $213,968 | $30,671 |
| 2014 | 21 | 34 | 62 | 1.74 | $89,100 | $13,078 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 1 service
| New patient visit (60+ min) | 14 | $1,968 | $141 |
2020: 1 service
| Removal of muscle and/or tissue, 20.0 sq cm or less | 11 | $3,995 | $133 |
2019: 2 services
| Removal of skin and tissue, 20.0 sq cm or less | 19 | $2,656 | $55 |
| Short return visit (20+ min) | 12 | $689 | $46 |
2018: 1 service
| Removal of skin and tissue, 20.0 sq cm or less | 20 | $2,706 | $56 |
2017: 1 service
| Removal of skin and tissue, 20.0 sq cm or less | 25 | $3,604 | $50 |
2016: 1 service
| Removal of skin and tissue, 20.0 sq cm or less | 24 | $3,164 | $51 |
2015: 3 services
| New patient visit (60+ min) | 15 | $2,096 | $140 |
| Removal of skin and tissue, 20.0 sq cm or less | 17 | $1,643 | $57 |
| Return visit (30+ min) | 14 | $1,332 | $70 |
Money from drug and device companies
$19,444 in 2025
| 2025 | 10 | 29 | $17,875 | $19,444 |
| 2024 | 4 | 9 | $12,981 | $14,975 |
| 2023 | 4 | 5 | $31,888 | $32,145 |
| 2022 | 5 | 13 | $13,825 | $16,012 |
| 2021 | 4 | 11 | $9,748 | $10,358 |
| 2020 | 4 | 6 | $18,022 | $18,022 |
| 2019 | 5 | 15 | $11,742 | $16,202 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Davol | Galaflex | $14,257 | 8 payments
|
| Abbvie | Natrelle Saline-Filled Breast Implants | $3,027 | 8 payments
|
| Solventum | Prevena | $800 | 1 payment
|
| Bimini Technologies | None | $500 | 1 payment
|
| Integra LifeSciences | Omnigraft | $277 | 3 payments
|
| Mentor Worldwide | Mentor Memorygel Resterilizable Gel Sizer | $220 | 2 payments
|
See all 29 published payments
| Abbvie | Meals · 2025-12-22 | Natrelle Saline-Filled Breast Implants | $19 |
| Tactile Systems Technology | Meals · 2025-12-13 | Flexitouch Plus | $72 |
| Davol | Honoraria · 2025-12-12 | None | $3,325 |
| Mentor Worldwide | Meals · 2025-11-11 | Mentor Memorygel Resterilizable Gel Sizer | $118 |
| Abbvie | Meals · 2025-11-04 | Natrelle Saline-Filled Breast Implants | $17 |
| TELA Bio | Meals · 2025-10-28 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) | $79 |
| Solventum | Consulting · 2025-10-27 | Prevena | $800 |
| Davol | Consulting · 2025-10-27 | None | $5,225 |
| Davol | Honoraria · 2025-10-27 | None | $2,150 |
| Abbvie | Meals · 2025-10-16 | Natrelle Saline-Filled Breast Implants | $101 |
| Abbvie | Meals · 2025-10-11 | Natrelle Saline-Filled Breast Implants | $146 |
| Davol | Meals · 2025-10-10 | Galaflex | $140 |
| Integra LifeSciences | Meals · 2025-10-10 | Integra | $14 |
| W. L. Gore & Associates | Meals · 2025-10-02 | Gore Bio-A Tissue Reinforcement | $59 |
| Abbvie | Consulting · 2025-08-20 | None | $2,550 |
| Abbvie | Meals · 2025-07-25 | Alloderm | $133 |
| Davol | Consulting · 2025-07-16 | None | $950 |
| Davol | Consulting · 2025-07-16 | None | $950 |
| Mentor Worldwide | Meals · 2025-06-12 | Mentor Memorygel Resterilizable Gel Sizer | $101 |
| Davol | Consulting · 2025-06-12 | None | $1,425 |
| Integra LifeSciences | Meals · 2025-05-17 | Omnigraft | $100 |
| Integra LifeSciences | Meals · 2025-05-08 | Omnigraft | $164 |
| Davol | Meals · 2025-04-30 | Phasix Mesh | $92 |
| Abbvie | Meals · 2025-04-23 | Alloderm | $51 |
| Abbvie | Meals · 2025-04-10 | Natrelle Saline-Filled Breast Implants | $11 |
| Bimini Technologies | Honoraria · 2025-03-26 | None | $500 |
| Novo Nordisk US Research & Development | Meals · 2025-02-19 | None | $17 |
| Novo Nordisk US Research & Development | Meals · 2025-02-19 | None | $2 |
| Novo Nordisk US Research & Development | Meals · 2025-02-18 | None | $135 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $14,975
| Novo Nordisk AS | None | $14,680 | 6 payments
|
| W. L. Gore & Associates | Gore Enform Preperitoneal Biomaterial | $164 | 1 payment
|
| Abbvie | Natrelle Saline-Filled Breast Implants | $107 | 1 payment
|
| TELA Bio | Ovitex 2s | $25 | 1 payment
|
2023: $32,145
| Molnlycke Health Care US | None | $29,750 | 1 payment
|
| Medline Industries Lp | None | $2,138 | 1 payment
|
| Mentor Worldwide | Artoura Breast Tissue Expander | $132 | 2 payments
|
| Integra LifeSciences | Integra | $126 | 1 payment
|
2022: $16,012
| Molnlycke Health Care US | Avance Solo | $9,814 | 8 payments
|
| Medline Industries LP | None | $3,325 | 2 payments
|
| Davol | None | $2,750 | 1 payment
|
| Rti Surgical | Cortiva Allograft Dermis | $74 | 1 payment
|
| Aroa Biosurgery | None | $49 | 1 payment
|
2021: $10,358
| Medline Industries | Dermatology and Wound Care | $5,470 | 5 payments
|
| Davol | None | $3,625 | 3 payments
|
| Misonix | None | $1,200 | 2 payments
|
| Molnlycke Health Care US | Mepilex | $63 | 1 payment
|
2020: $18,022
| Misonix | None | $8,235 | 1 payment
|
| Medline Industries | Dermatology and Wound Care | $5,663 | 3 payments
|
| Davol | None | $3,125 | 1 payment
|
| Molnlycke Health Care US | None | $1,000 | 1 payment
|
2019: $16,202
| Medline Industries | Dermatology and Wound Care | $9,597 | 8 payments
|
| Osiris Therapeutics | Grafixpl | $6,082 | 4 payments
|
| Wound Management Technologies | Celleraterx | $400 | 1 payment
|
| Acell | None | $94 | 1 payment
|
| Misonix | Theraskin | $29 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Allergan, Inc. · 2020 | Their institution | $19,851 |
| Mentor Worldwide LLC · A Study of the Safety and Effectiveness of the Mentor Larger Size Memorygel Ultra High Profile Breast Implants in Subjects Who Are Undergoing Primary Breast Reconstruction Or Revision Reconstruction · 2020 | Their institution | $17,400 |
| Mentor Worldwide LLC · A Study of the Safety and Effectiveness of the Mentor Larger Size Memorygel Ultra High Profile Breast Implants in Subjects Who Are Undergoing Primary Breast Reconstruction Or Revision Reconstruction · 2021 | Their institution | $7,309 |
| Medical Device Business Services, Inc. · Men-15-001 A Study of the Safety and Effectiveness of the Mentor Larger Size Memorygel Ultra High Profile Breast Implants in Subjects Who Are Undergoing Primary Breast Reconstruction Or Revision Reconstruction (Athena) · 2019 | Their institution | $7,249 |
| Mentor Worldwide LLC · A Study of the Safety and Effectiveness of the Mentor Larger Size Memorygel Ultra High Profile Breast Implants in Subjects Who Are Undergoing Primary Breast Reconstruction Or Revision Reconstruction · 2022 | Their institution | $4,441 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 97.6 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1891830881
- Licence
- CA A93283California A93283: Current · expires 2027-06-30
- Trained
- University of California, San Francisco School of Medicine, 1989 · 37 years ago
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Plastic and reconstructive surgery (2086S0122X)
- Mailing address
- 257 Campus Drive Bldg Psrl, Mc 5148 Rm Gk 201, Stanford, CA, 94305
- NPI first listed
- 2007-02-20
- NPI last updated
- 2017-01-13
This is when the NPI record was last certified, not a medical board exam.